A recently awarded Medicare new-technology add-on payment for NeuroPace Inc.RNS responsive neurostimulator system could provide a major boost to the company’s efforts to bring the anti-seizure therapy to all of the top epilepsy centers in the U.S., CEO Frank Fischer said in an interview.
RNS became the first responsive implantable neurostimulator commercially available in the U.S. in November 2013. FDA approved the device to...